Denali Therapeutics (NASDAQ:DNLI) Stock Price Target Raised at Wedbush

Denali Therapeutics (NASDAQ:DNLI) had its price objective hoisted by investment analysts at Wedbush from $23.00 to $24.00 in a report released on Wednesday, Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Wedbush‘s target price suggests a potential upside of 23.39% from the stock’s current price.

Other analysts have also recently issued research reports about the company. Morgan Stanley lifted their price objective on Denali Therapeutics from $35.00 to $36.00 and gave the stock an “overweight” rating in a research report on Thursday, July 23rd. JPMorgan Chase & Co. initiated coverage on Denali Therapeutics in a research note on Monday, July 13th. They issued an “overweight” rating and a $29.00 target price for the company. Deutsche Bank Aktiengesellschaft increased their target price on Denali Therapeutics from $31.00 to $35.00 and gave the stock a “buy” rating in a research report on Thursday, July 16th. B. Riley Financial raised their price target on Denali Therapeutics from $30.00 to $35.00 and gave the stock a “buy” rating in a research note on Tuesday, August 25th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Denali Therapeutics in a report on Thursday, October 15th. Thirteen investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $35.69.

Denali Therapeutics Stock Up 3.1%

Denali Therapeutics stock opened at $19.45 on Wednesday. The stock’s 50 day moving average price is $20.42 and its 200 day moving average price is $21.24. Denali Therapeutics has a 1-year low of $13.75 and a 1-year high of $27.30. The company has a market cap of $3.11 billion, a PE ratio of -6.85 and a beta of 1.08. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.37 and a quick ratio of 8.32.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings data on Tuesday, November 3rd. The company reported $0.37 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.64. The business had revenue of $17.78 million during the quarter, compared to analysts’ expectations of $12.67 million. During the same quarter in the previous year, the company posted ($0.74) EPS. On average, sell-side analysts predict that Denali Therapeutics will post -2.70 EPS for the current fiscal year.

Insider Buying and Selling

In other Denali Therapeutics news, insider Alexander O. Schuth sold 2,857 shares of the business’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $25.07, for a total transaction of $71,624.99. Following the transaction, the insider owned 281,763 shares in the company, valued at $7,063,798.41. The trade was a 1.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 9.70% of the stock is owned by company insiders.

Hedge Funds Weigh In On Denali Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. bought a new position in shares of Denali Therapeutics during the second quarter worth about $360,759,000. ADAR1 Capital Management LLC grew its stake in Denali Therapeutics by 3,490.9% in the first quarter. ADAR1 Capital Management LLC now owns 1,871,455 shares of the company’s stock worth $35,932,000 after purchasing an additional 1,819,339 shares in the last quarter. Bank of America Corp DE bought a new stake in Denali Therapeutics in the second quarter valued at about $31,660,000. Bank of New York Mellon Corp bought a new stake in Denali Therapeutics in the second quarter valued at about $20,583,000. Finally, Defilade Capital Management L.P. raised its stake in Denali Therapeutics by 107.1% during the first quarter. Defilade Capital Management L.P. now owns 1,359,969 shares of the company’s stock valued at $26,111,000 after buying an additional 703,256 shares in the last quarter. Institutional investors and hedge funds own 92.92% of the company’s stock.

Key Stories Impacting Denali Therapeutics

Here are the key news stories impacting Denali Therapeutics this week:

• Positive Sentiment: AVLAYAH generated $17.8 million in net product revenue in its second full commercial quarter. Denali forecast fourth-quarter revenue of $30 million to $32 million, signaling expected acceleration in sales. Denali Q3 2026 results
• Positive Sentiment: BTIG Research reaffirmed its Buy rating and set a $39 price target, substantially above the cited current price of $19.45. BTIG Research ratings
• Positive Sentiment: Denali said its zafinofusp BLA submission remains on track for 2027, and expects data in 2027 from five TransportVehicle programs. These milestones offer potential future catalysts, though they remain subject to development and regulatory risk. Denali Q3 2026 results
• Negative Sentiment: Quarterly net income of $70.1 million included a one-time $194 million gain from selling a Priority Review Voucher, so it may overstate recurring earnings strength. Zacks separately reported a $0.64 per-share loss, narrower than expected and improved from a year earlier. Zacks Q3 earnings report

About Denali Therapeutics

Denali Therapeutics Inc is a biopharmaceutical company focused on discovering and developing therapies for patients with neurodegenerative diseases. The company’s research programs target conditions including Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis, and lysosomal storage disorders.

Denali uses its blood-brain barrier transport technology, known as the Transport Vehicle platform, to design medicines intended to deliver therapeutic proteins and other biologic treatments into the central nervous system.